# A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

> **NCT05941936** · EARLY_PHASE1 · UNKNOWN · sponsor: **Suzhou BlueHorse Therapeutics Co., Ltd.** · enrollment: 5 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** LM103

## Key facts

- **NCT ID:** NCT05941936
- **Lead sponsor:** Suzhou BlueHorse Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-19
- **Primary completion:** 2025-02
- **Final completion:** 2026-02
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2023-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941936, "A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05941936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*